OINDPnews


Proveris Scientific

Business

Aradigm’s Pulmaquin will get EMA review under centralized procedure

Aradigm Corporation has announced that the EMA will review an Aradigm MAA for Pulmaquin inhaled liposomal ciprofloxacin under the centralized authorization procedure. According to the company, "Aradigm requested, and was granted, the centralized pathway on the basis that Pulmaquin represents a significant technical innovation for the potential treatment of non-cystic … [Read more...] about Aradigm’s Pulmaquin will get EMA review under centralized procedure

Vectura to acquire Skyepharma

Inhaled drug manufacturers Vectura and Skyepharma have announced a merger agreement in which Vectura will acquire Skyepharma for a total of £441 million ($638 million). Both boards have approved the merger. Vectura previously acquired Activaero in 2014. Vectura CEO James Ward-Lilley will continue as CEO and Vectura Chairman Bruno Angelici will continue as Chairman … [Read more...] about Vectura to acquire Skyepharma

MannKind announces 4th quarter results, management changes

According to MannKind Corporation, the company's net loss for 2015 was $368.4 million, and its cash and cash equivalents as of the end of 2015 totaled $59.1 million. The company also said that it has hired former Amgen VP, Global Commercial Lead Michael E. Castagna as its Chief Commercial Officer, effective immediately, and announced the resignation of Chief Operating … [Read more...] about MannKind announces 4th quarter results, management changes

Children’s Flonase now available OTC in the United States

GSK Consumer Healthcare has announced that Children's Flonase fluticasone propionate nasal spray is now available over the counter in the US. The FDA approved OTC sales of Flonase in July 2014, and the product has been available over the counter in the US since February 2015. Children's Flonase appears to be effectively identical to regular Flonase, with 50 mcg of … [Read more...] about Children’s Flonase now available OTC in the United States

Cannabinoid developer to collaborate with intranasal delivery company on epilepsy therapy

Australian medical cannabis company MGC Pharmaceuticals has signed a collaboration agreement with Israeli device developer SipNose for development of a cannabinoid therapy for the treatment of epilepsy, the company said. The agreement includes an option for a global license for use of the SipNose device to deliver cannabinoids for epilepsy. According to MGC, the … [Read more...] about Cannabinoid developer to collaborate with intranasal delivery company on epilepsy therapy

Savara Pharmaceuticals raises $20 million for AeroVanc development

Savara Pharmaceuticals has announced the completion of a $20 million financing round to fund a pivotal Phase 3 clinical trial of its AeroVanc vancomycin DPI for the treatment of MRSA lung infections in cystic fibrosis patients. The company says that it expects enrollment for the study to begin by the end of the year. In February 2015, Savara announced positive … [Read more...] about Savara Pharmaceuticals raises $20 million for AeroVanc development

Impel NeuroPharma licenses intranasal therapy for depression

Intranasal delivery specialist Impel NeuroPharma and the Toronto-based Centre for Addiction and Mental Health (CAMH) have signed a licensing agreement for an intranasal neuropeptide-based therapy for the treatment of depression. The peptide, which was discovered at CAMH, will be delivered using Impel's Precision Olfactory Delivery (POD) device. According to CAMH, … [Read more...] about Impel NeuroPharma licenses intranasal therapy for depression

Alexza Pharmaceuticals signs non-binding letter of intent with Grupo Ferrer

Inhaled drug developer Alexza Pharmaceuticals has signed a non-binding letter of intent and entered into discussions with Grupo Ferrer regarding Ferrer's acquisition offer, the company said. Alexza noted that the letter of intent allows the company to continue to explore other options, and there is no guarantee that it will complete the deal with Ferrer. In … [Read more...] about Alexza Pharmaceuticals signs non-binding letter of intent with Grupo Ferrer